Study on the Accessibility and Feasibility of Intelligent Applet for Health Intervention of Cancer Patients
Launched by RUIJIN HOSPITAL · Aug 12, 2022
Trial Information
Current as of August 19, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying a new app designed to help manage the health of cancer patients before and after surgery. The app aims to make communication between patients and doctors easier and more effective, especially in the fast-paced digital world we live in today. By improving how cancer care is delivered through technology, the researchers hope to enhance patient outcomes and overall health management.
To participate in this trial, you need to be a cancer patient who can use a smartphone and access the internet. You should also be able to understand and follow the instructions provided during the study. If you have a serious medical condition, such as a heart device, you may not be eligible. Participants can expect to engage with the app throughout their treatment, helping to improve their care experience. This trial is currently recruiting participants of all genders, typically aged 65 and older, who are willing to contribute to this important research.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Sign and date informed consent;
- • Commit to abide by the research procedures and cooperate with the implementation of the whole research process ;
- • Can adhere to and cooperate with research intervention;
- • Tumor patients;
- • Patients/family members can use smart phones to access the Internet;
- • Patients/family members have sufficient cognitive and reading ability;
- • No mental illness;
- • No serious visual impairment
- Exclusion Criteria:
- • Equipped with specific devices (such as cardiac pacemaker);
- • Those who do not meet the conditions listed in the inclusion criteria.
About Ruijin Hospital
Ruijin Hospital, affiliated with Shanghai Jiao Tong University School of Medicine, is a leading medical institution in China recognized for its commitment to advancing healthcare through innovative research and clinical trials. With a strong emphasis on patient-centered care, Ruijin Hospital integrates cutting-edge medical practices with rigorous scientific investigation. The hospital's multidisciplinary teams are dedicated to developing new therapeutic approaches, improving patient outcomes, and contributing to global medical knowledge. As a sponsor of clinical trials, Ruijin Hospital ensures adherence to the highest ethical standards and regulatory compliance, fostering an environment of collaboration and excellence in clinical research.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Shanghai, , China
Patients applied
Trial Officials
Lei Huang, PhD, MD
Principal Investigator
Ruijin Hospital
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials